Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,315 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Oncology Care Clear all
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions
CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

NCT06498661
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Terminated Phase 3 Interventional Results available

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

NCT01310803
View directory record Official record
Conditions
Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
Interventions
VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Phoenix, Arizona • Denver, Colorado • Cumberland, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

NCT00673010
View directory record Official record
Conditions
Thyroid Cancer
Interventions
131 I-iodine (131-I), 124 I-iodine (124-I)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

NCT06036810
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Shared Medical Decision Tool, Engaging Patients in Decision Making, Literacy Spanish Language
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 3 Interventional

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Cemiplimab, Standard of care
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

NCT04993313
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Breast Carcinoma
Interventions
Counseling, Educational Intervention, Questionnaire
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional

A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors

NCT06198010
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Best Practice, Educational Intervention, Questionnaire Administration, Electronic Health Record Review, Health Telemonitoring, Cancer Pain Management
Other · Procedure · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

NCT06145412
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapan, Cisplatin, External beam
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional

Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

NCT07502352
View directory record Official record
Conditions
Breast Cancer
Interventions
Remotely Delivered Cognitive Behavioral Stress Management Intervention (R-CBSM), Standard of Care Survivorship Care Planning
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

NCT02662335
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Computer-Assisted Cognitive Training, Questionnaire Administration, Standard Follow-Up Care
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

NCT04991025
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Interventions
Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab, Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure
Procedure · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

NCT02990468
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
BMX-001, Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Withdrawn Early Phase 1 Interventional

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

NCT03718650
View directory record Official record
Conditions
Pancreatic Cancer, Resectable Pancreatic Cancer
Interventions
Pimonidazole, Surgical Resection
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Abemaciclib in Recurrent Glioblastoma

NCT02981940
View directory record Official record
Conditions
Glioblastoma
Interventions
Abemaciclib, Surgery
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

NCT07107750
View directory record Official record
Conditions
Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions
Emavusertib, Gemcitabine, Cisplatin, Durvalumab
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

NCT06534125
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy, Discussion, Survey Administration
Procedure · Device · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

NCT07405476
View directory record Official record
Conditions
Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Zanidatamab, Resection, Patient Observation, Echocardiography Test, Multigated Acquisition Scan, Endoscopic Procedure, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy Procedure, Digital Rectal Examination, Electronic Health Record Review
Biological · Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan, JNJ-101556143
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival

NCT00519168
View directory record Official record
Conditions
Breast Cancer
Interventions
Urine sample, Electrode sleep recorder, phlebotomy
Procedure · Device
Lead sponsor
Stanford University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 16, 2026, 2:15 PM EDT